Chemotherapy and the war on cancer
- B. Chabner, T. Roberts
- MedicineNature Reviews. Cancer
- 2005
The history of modern chemotherapy is chronicles and remaining challenges for the next generation of researchers are identified.
Polyglutamation of methotrexate. Is methotrexate a prodrug?
- B. Chabner, C. Allegra, J. Jolivet
- Medicine, BiologyJournal of Clinical Investigation
- 1 September 1985
Leur etude decrit l'importance pharmacologique de la polyglutamation du methotrexate de la Polyglutamyl synthetase.
The National Cancer Institute: cancer drug discovery and development program.
- M. Grever, S. Schepartz, B. Chabner
- MedicineSeminars in Oncology
- 1 December 1992
An update on the NCI's revised cancer screen is accompanied by a brief summary of those new agents scheduled to be entered into clinical investigation in the near future.
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
- W. Wilson, K. Dunleavy, J. Janik
- Medicine, BiologyJournal of Clinical Oncology
- 1 June 2008
DA-EPOCH-R outcome was not affected by tumor proliferation and rituximab appeared to overcome the adverse effect of Bcl-2, and bcl-6 may identify a biologic program associated with a superior outcome.
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.
- T. Roberts, B. Goulart, Jeffrey W. Clark
- MedicineJAMA
- 3 November 2004
The level of risk experienced by cancer patients who participate in phase 1 treatment trials appears to have improved over the 12-year period from 1991 through 2002, and the ratio of risk to benefit may have also improved.
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
- W. Wilson, M. Grossbard, F. Balis
- MedicineBlood
- 15 April 2002
Dose-adjusted EPOCH may produce more cell kill than CHOP-based regimens and Expression of bcl-2 may discriminate the recently described activated B-like from germinal-center B- like large-cell lymphomas and provide important pathobiologic and prognostic information.
Cancer Chemotherapy and Biotherapy: Principles and Practice
- B. Chabner, D. Longo
- Biology, Medicine
- 15 June 2001
Clinical Strategies for Cancer Treatment: The Role of Drugs Preclinical Aspects of Cancer Drug Discovery and Development Pharmacokinetics and Clinical Monitoring Infertility after Cancer Chemotherapy…
The pharmacology and clinical use of methotrexate.
- J. Jolivet, K. Cowan, G. Curt, N. Clendeninn, B. Chabner
- Medicine, BiologyNew England Journal of Medicine
- 3 November 1983
METHOTREXATE, the most widely used antimetabolite in cancer chemotherapy, has an essential role in the treatment of such diverse diseases as acute lymphocytic leukemia, non-Hodgkin's lymphoma, oste...
Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates.
- C. Allegra, J. Drake, J. Jolivet, B. Chabner
- Chemistry, BiologyProceedings of the National Academy of Sciences…
- 1 August 1985
The enhanced inhibitory potency of methotrexate (MTX) polyglutamates and dihydrofolate pentaglutamate on the catalytic activity of AICAR transformylase purified from MCF-7 human breast cancer cells is reported and a model depicting these complex interactions is postulated.
Application of Cell-free DNA Analysis to Cancer Treatment.
- R. Corcoran, B. Chabner
- Biology, MedicineNew England Journal of Medicine
- 31 October 2018
The capacity to detect new cancers, treatment-resistant variants, and tumor heterogeneity by noninvasive technology on the basis of tumor DNA in oncology by non invasive technology is demonstrated.
...
...